StreetAlpha.app
Home › Stocks › VTRS

Viatris Inc (VTRS)

Healthcare
$19.63
▼ −1.26%
LAST CLOSE · NOV 20

Viatris makes and sells generic, branded and newer medicines for patients around the world. It last closed at $19.63 on Nov 20, down 1.26% on the day. The next earnings report for VTRS is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, VTRS reported EPS of -$0.28 on revenue of $3.75B, with revenue down 0.3% from a year ago. Over its last 8 reports the stock moved an average of 7.2% the session after earnings. Over the last 12 months VTRS insiders bought $0 of stock on the open market and sold $1.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is VTRS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VTRS.

Key Stats

Last 12 months
Results
Revenue
$14.7B
+4.3% vs a year ago
EPS (diluted)
−$0.53
Free cash flow
$2.1B
14.3% margin
Gross margin
35.3%
$5.2B gross profit
Valuation
Market cap
$22.5B
1.15B shares
P/E
–
No P/E while losing money
Price to sales
1.5
Market cap over revenue
Dividend yield
2.45%
$0.48 a share over 12 months
Balance sheet
Cash & equivalents
$1.8B
At Sep 30
Debt
$13.3B
At Sep 30
Buybacks
$385.1M
Last 12 months
CEOScott A. Smith
Employees30,000 (Dec 31, 2025)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $17.9B$17.9BFY2021FY2022: $16.3B$16.3BFY2022FY2023: $15.4B$15.4BFY2023FY2024: $14.7B$14.7BFY2024FY2025: $14.3B$14.3BFY2025

From VTRS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$0.28
Quarter ended Sep 2026
Year ago EPS
-$0.11
Same quarter last year
Revenue
$3.75B
−0.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.43Dec '24Mar 2025: -$2.55Mar '25Jun 2025: $0.00Jun '25Sep 2025: -$0.11Sep '25Dec 2025: -$0.30Dec '25Mar 2026: $0.15Mar '26Jun 2026: -$0.10Jun '26Sep 2026: -$0.28Sep '26Latest -$0.28
Revenue by quarter
Dec 2024: $3.53BDec '24Mar 2025: $3.25BMar '25Jun 2025: $3.58BJun '25Sep 2025: $3.76BSep '25Dec 2025: $3.70BDec '25Mar 2026: $3.52BMar '26Jun 2026: $3.76BJun '26Sep 2026: $3.75BSep '26Latest $3.75B
How VTRS moved after its last 8 reports
Average move the session after a report ±7.2%
Nov 5, 2026Time not announced−1.3%
Aug 6, 2026Time not announced−7.7%
May 7, 2026Time not announced+9.0%
Feb 26, 2026Time not announced−5.2%
Nov 6, 2025Time not announced−6.0%
Aug 7, 2025Time not announced+7.3%
May 8, 2025Time not announced+5.7%
Feb 27, 2025Time not announced−15.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on VTRSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on VTRS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on VTRS

Technical Analysis

VTRS · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 52). The nearest support is the Pivot S1 at $19.34, and the nearest resistance the Pivot at $19.72.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 2.8%/day
Key levels
$21.2052 week high+8.0%
$21.20Swing high (Nov 12)+8.0%
$20.01Pivot R1+1.9%
$19.7320 day average+0.5%
$19.72Pivot+0.5%
$19.63Last close
$19.34Pivot S1−1.5%
$18.64Swing low (Nov 3)−5.0%
$18.4750 day average−5.9%
$17.63100 day average−10.2%
$16.40200 day average−16.5%
$10.1552 week low−48.3%
Indicators
RSI (14)52.17Middle of its rangeNeutral
MACD0.55Below its signal lineBearish
Stochastic50.4Middle of its rangeNeutral
ADX (14)32.9Trending up
Williams %R-61.3Oversold below −80, overbought above −20Neutral
CCI (20)0.7Oversold below −100, overbought above 100Neutral
Rate of change−1.4%Change over 10 sessionsBearish
ATR (14)$0.56Typical daily range, 2.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for VTRS

What happened before

See how VTRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow VTRS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How VTRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for VTRSHow many large options trades hit VTRS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

VTRS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲475 buying vs 409 selling
  • ▼Held by funds -2.1 pts
  • ●Funds holding +2
  • ▲Superinvestors: 5 added, 1 cut
  • ▲Put/call 0.30 to 0.18
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1,0381,036+0.2%
In funds' top 101516−6.3%
Held by funds89.6%91.7%−2.1 pts
New / increased99 / 37697 / 370+1.7%
Reduced / sold out319 / 90324 / 98−3.1%
Put/call ratio0.180.30−38.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VTRS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VTRS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.1M2 sales · 1 insider
74% of the selling was under pre-arranged trading plans.
2026-03 sold $284K2026-06 sold $810KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 25Paul CampbellSee RemarksSale plan50,076$16.17$810K
Mar 23Paul CampbellSee RemarksSale21,350$13.28$284K
Nov 3, 2025David S SimmonsDirectorBuy499$10.42$5K
Sep 11, 2025Goff Corinne LeChief Commercial OfficerSale plan7,032$10.25$72K
Aug 12, 2025Scott Andrew SmithCEOBuy22,000$9.99$220K
May 12, 2025Scott Andrew SmithCEOBuy60,000$8.94$536K
Every insider buy and sale for VTRS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See VTRS insider trades →

From SEC Form 4 filings by VTRS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

VTRS Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$385.1M
1.7% yield
Left in program
$699.5M
3.1% of value
Shares outstanding, 12 months
−0.5%
Fewer shares
Last quarter
$150.0M
Sep 2026
Avg price paid, last quarter
$16.83
8.9M shares bought
S&P 500 rank by spending
#295 of 358
 
Spent each quarter, last 3 yearsTop bar $249.6M
Dec 2023: $0Mar 2024: $249.6M, average price $12.97Jun 2024: $0Sep 2024: $0Dec 2024: $0Mar 2025: $175.5M, average price $9.43Jun 2025: $175.0M, average price $8.65Sep 2025: $68.0M, average price $10.01Dec 2025: $82.1M, average price $10.20Mar 2026: $0Jun 2026: $150.0M, average price $16.01Sep 2026: $150.0M, average price $16.83
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Nov 5, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VTRS is in one of them and how their past VTRS trades turned out.

VTRS in the AI portfolios
Loading…

VTRS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VTRS in an article yet. Here's the latest on the wider market.

VTRS in the news

VTRS Congress Trades

All congress trades →
Trades, 12 months
1
Buys
1
100%
Sells
0
0%
People
1
Last filed Dec 15
Who traded VTRS · since 2020
Latest 5 filings of 22
$1K – $15KTraded Nov 18, 2025Filed Dec 15, 2025
$1K – $15KTraded Apr 8, 2025Filed May 8, 2025
Gilbert CisnerosSell (partial)
$1K – $15KTraded Mar 31, 2025Filed Apr 7, 2025
$1K – $15KTraded Feb 25, 2025Filed Mar 27, 2025
Dan GoldmanSell (partial)
$1K – $15KTraded Apr 10, 2023Filed May 19, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KNov 18, 2025Dec 15, 202527 d
Rob BresnahanR · PASell$1K – $15KApr 8, 2025May 8, 202530 d
Gilbert CisnerosD · CASell (partial)$1K – $15KMar 31, 2025Apr 7, 20257 d
Rob BresnahanR · PABuy$1K – $15KFeb 25, 2025Mar 27, 202530 d
Dan GoldmanD · NYSell (partial)$1K – $15KApr 10, 2023May 19, 202339 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Viatris

Viatris is a healthcare company based in Canonsburg, Pennsylvania, that makes and sells medicines for patients around the world. Its portfolio includes generic medicines, including complex products, familiar branded medicines, and newer medicines it is developing. It runs manufacturing, packaging and distribution sites worldwide and serves patients and other customers in many countries.

Headquarters
Canonsburg, PA
Founded
2020